A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Clinical trial NCT00240253 · COMPLETED

Trial details

NCT number: NCT00240253
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Type 2 Diabetes Mellitus

Start date: 2005-10-01
Primary completion: 2006-06-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.